Dojolvi

Active Ingredient(s): Triheptanoin
FDA Approved: * June 30, 2020
Pharm Company: * ULTRAGENYX PHARM INC
Category: Genetic Disorders

Triheptanoin, sold under the brand name Dojolvi, is a medication for the treatment of children and adults with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).[1][2][3] The most common adverse reactions include abdominal pain, diarrhea, vomiting, and nausea.[1][2][3] Triheptanoin was approved for medical use in the United States in June 2020.[4][2&a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Dojolvi .96 g/ml Oral Liquid

NDC: 69794-050

Labeler:

Ultragenyx Pharmaceutical Inc.